← All trials
NCT04627428
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2021
- Primary completion
- Feb 28, 2025
- Completion date
- Feb 28, 2025
- First posted
- Nov 13, 2020
- Last posted
- Sep 16, 2021
- Enrollment
- 18
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Luxa Biotechnology, LLCLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Eye Institute (NEI)Collaborator
- University of MichiganOverall official - principal investigator
- Regenerative Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.